LARS2-AS1

Across TCGA pan-cancer cohorts, LARS2-AS1 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated LARS2-AS1 data layer.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher LARS2-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LARS2-AS1 expression acts as an unfavorable survival marker, although some lineages such as LGG and UCS show a favorable association.

ACC, KIRC, and UVM are the cancer types where LARS2-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Quartile	All	0.363	0.747	<.001	95	view →
KIRC	OS	Quartile	All	0.454	0.673	<.001	93	view →
UVM	OS	Tertile	All	0.280	0.796	<.001	45	view →
MESO	OS	Tertile	III,IV	0.209	0.617	.011	33	view →
LUSC	DFS	Median	III,IV	0.432	0.942	.010	28	view →
LGG	DFS	Quartile	All	0.864	0.679	<.001	27	view →
READ	DFS	Quartile	IV	0.334	0.691	<.001	25	view →
UCS	DFS	Median	IV	0.909	0.416	.008	18	view →
GBM	DFS	Tertile	All	0.169	0.311	.001	15	view →
SKCM	DFS	Quartile	II,III,IV	0.537	0.760	.009	12	view →
ESCA	DFS	Quartile	All	1.000	0.302	.011	9	view →
LIHC	OS	Tertile	All	0.378	0.631	.027	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

LARS2-AS1–ACC (DFS)

Open the ACC breakdown →